AHA 23 Late-Breaker Discussion: The SELECT Trial

Published: 17 Nov 2023

  • Views:

    Views Icon 653
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

AHA 2023 — Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) sat down with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the SELECT trial (NCT03574597).

In this randomized, double-blind, parallel-group, placebo-controlled trial sponsored by Novo Nordisk, semaglutide was compared with a placebo in patients who have overweight or obesity and a history of cardiovascular disease. A total of 17,609 participants were enrolled by the investigators. In the investigator arm, participants received semaglutide injections as an adjunct to standard-of-care. The primary endpoint of this trial is the time to the first occurrence of a composite endpoint, which includes cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia. 

For more content from #AHA23 head to the Late-Breaking or the CardioNerds Conference Scholars Collection.

Support: This is an independent discussion produced by Radcliffe Cardiology.

Editor: Mirjam Boros, Jordan Rance
Videographers: Dan Brent, Mike Knight


You must be to comment. If you are not registered, you can register here.